monoclonal antibodies as immune modulators for cancer therapy
Clicks: 171
ID: 152934
1992
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
171 views
31 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #20 of 60 articles by views in computer science
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Monoclonal antibodies may modulate immune and/or biological responses
alone, or as carriers of specific agents. Monoclonal antibodies directed against tumours may be indirectly
cytotoxic by modulation of antibody-dependent, cell-mediated cytotoxicity or complement-mediated
cytotoxicity. Monoclonal antibodies directed against certain tumour cell receptors may alter the biological
behaviour of tumour cells such as blocking or downregulation of growth factors essential to tumour cell
proliferation. Monoclonal antibodies directed to certain receptors on host immune cells. such as the CD3
receptor on T lymphocytes. may activate those cells and increase their cytotoxicity. Antitumour monoclonal
antibodies can serve as carriers of interferons, interleukin-2, tumour necrosis factor and other lymphokines
and cytokines to modulate selectively the cytotoxic potential of immune cells in the vicinity of tumour cells.
Cytotoxic chemotherapy agents conjugated to antitumour monoclonal antibodies may be processed
differently so that they bypass certain mechanisms of drug resistance. The penultimate application of
monoclonal antibodies in cancer therapy is to combine various monoclonal antibodies and immunoconjugates
for selective combination therapy based on known antigenic tumour cell determinants and the
status of the host immune system.
| Reference Key |
dillman1992canadianmonoclonal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Robert O Dillman |
| Journal | computer science |
| Year | 1992 |
| DOI |
10.1155/1992/205769
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.